We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biglycan in the Tumor Microenvironment May Act As Metastasis Trigger

By LabMedica International staff writers
Posted on 25 Jul 2016
Print article
Image: A strong biglycan signal (red) was detected in the tumor blood vessel area of a metastatic case (right) but was barely detected in the tumor tissues of a non-metastatic case (left) (Photo courtesy of Maishi N. et al., Scientific Reports).
Image: A strong biglycan signal (red) was detected in the tumor blood vessel area of a metastatic case (right) but was barely detected in the tumor tissues of a non-metastatic case (left) (Photo courtesy of Maishi N. et al., Scientific Reports).
A small proteoglycan secreted from endothelial cells within the tumor microenvironment has been linked to the likelihood of the primary tumor metastasizing and freeing cells to travel to other parts of the body.

Investigators at Hokkaido University (Japan) had demonstrated earlier that features of tumor endothelial cells (TECs) were different depending on tumor malignancy, suggesting that TECs communicated with surrounding tumor cells. However, the mechanism of this communication, especially its relation to metastasis, had not been elucidated.

In the current study, which was published in the June 13, 2016, online edition of the journal Scientific Reports, the investigators described the role of biglycan on tumor metastasis. Biglycan is a small leucine-rich repeat proteoglycan (SLRP) which is found in a variety of extracellular matrix tissues, including bone, cartilage, and tendon. In humans, biglycan is encoded by the BGN gene, which is located on the X chromosome. Biglycan consists of a protein core containing leucine-rich repeat regions and two glycosaminoglycan (GAG) chains consisting of either chondroitin sulfate (CS) or dermatan sulfate (DS), with DS being more abundant in most connective tissues.

The investigators reported that high biglycan expression was associated with poor prognosis in patients with breast, lung, and colorectal cancer. High levels of biglycan were found in the blood of patients with metastatic cancer, while the molecule was barely detectable in the non-metastatic disease.

The investigators also worked with mouse models of low-metastatic (LM) and high-metastatic (HM) melanoma tumors. They found that co-implantation of TECs isolated from highly metastatic tumors accelerated lung metastases of low metastatic tumors. Biglycan synthesis was upregulated by DNA demethylation in TECs, which secreted the substance, activating tumor cell migration via nuclear factor-kappaB.

The investigators said, "The present observations, together with unravelling certain remaining issues, may contribute to establishing accurate diagnostics or potent anti-metastatic strategies that target the communications between tumor cells and endothelial cells."

Related Links:
Hokkaido University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.